A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety of inhaled sodium pyruvate in
people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will
improve lung function, as determined by FEV1, or reduce inflammatory markers in induced
sputum of people with CF.
Phase:
Phase 1
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute